Trypsin in colorectal cancer: Molecular biological mechanisms of proliferation, invasion, and metastasis

Journal of Pathology

Volumn 209, Issue 2, 2006, Pages 147-156

  Soreide, K ^a   Janssen, E A ^a   Komer H ^a,b   Baak, J P A ^a,b,c  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Carcinogenesis; Colorectal cancer; Invasion; Matrix metalloproteinases; Metastasis; Proliferation; Protease activated receptor; Trypsin

Indexed keywords

BATIMASTAT; COLLAGEN TYPE 1; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GELATINASE A; GELATINASE B; MASPIN; MATRILYSIN; MATRIX METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; NEUTRALIZING ANTIBODY; PANCREAS ENZYME; PROSTAGLANDIN; PROTEIN TYROSINE KINASE INHIBITOR; PROTEINASE ACTIVATED RECEPTOR 2; SERINE PROTEINASE INHIBITOR; TETRACYCLINE DERIVATIVE; TRANSFORMING GROWTH FACTOR ALPHA; TRYPSIN;

AUTOCRINE EFFECT; BASEMENT MEMBRANE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER SURVIVAL; CARCINOGENESIS; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; DISEASE FREE SURVIVAL; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; METASTASIS; MITOGENICITY; MOLECULAR BIOLOGY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ADENOMA; CELL DIVISION; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; HUMANS; MATRIX METALLOPROTEINASES; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROSTAGLANDINS; RECEPTOR, PAR-2; RECEPTORS, PROTEINASE-ACTIVATED; TRYPSIN;

EID: 33744457678     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.1999     Document Type: Review

References (105)

1. Paju A, Vartiainen J, Haglund C, Itkonen O, von Boguslawski K, Leminen A, et al. Expression of trypsinogen-1, trypsinogen2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. Clin Cancer Res 2004;10:4761-4768.
2. Yamamoto H, Iku S, Adachi Y, Imsumran A, Taniguchi H, Nosho K, et al. Association of trypsin expression with tumour progression and matrilysin expression in human colorectal cancer. J Pathol 2003;199:176-184.
3. Solakidi S, Tiniakos DG, Petraki K, Stathopoulos GP, Markaki I, Androulakis G, et al. Co-expression of trypsin and tumour-associated trypsin inhibitor (TATI) in colorectal adenocarcinomas. Histol Histopathol 2003;18:1181-1188.
4. Williams SJ, Gotley DC, Antalis TM. Human trypsinogen in colorectal cancer. Int J Cancer 2001;93:67-73.
5. Nyberg P, Moilanen M, Paju A, Sarin A, Stenman UH, Sorsa T, et al. MMP-9 activation by tumor trypsin-2 enhances in vivo invasion of human tongue carcinoma cells. J Dent Res 2002;81:831-835.
6. Bjartell A, Paju A, Zhang WM, Gadalcanu V, Hansson J, Landberg G, et al. Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer. Prostate 2005;64:29-39.
7. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
8. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-170.
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
10. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet 2005;365:153-165.
11. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
12. Körner H, Soreide K, Stokkeland PJ, Söreide JA. Systematic follow-up after curative surgery for colorectal cancer in Norway: a population-based audit of effectiveness, costs, and compliance. J Gastrointest Surg 2005;9:320-328.
13. Boedefeld WM 2nd, Bland KI, Heslin MJ. Recent insights into angiogenesis, apoptosis, invasion, and metastasis in colorectal carcinoma. Ann Surg Oncol 2003;10:839-851.
14. DeClerck YA, Mercurio AM, Stack MS, Chapman HA, Zutter MM, Muschel RJ, et al. Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am J Pathol 2004;164:1131-1139.
15. Borg TK. It's the matrix! ECM, proteases, and cancer. Am J Pathol 2004;164:1141-1142.
16. Itkonen O, Stenman UH, Osman S, Koivunen E, Halila H, Schroder T. Serum samples from pancreatectomized patients contain trypsinogen immunoreactivity. J Lab Clin Med 1996;128:98-102.
17. Koshikawa N, Hasegawa S, Nagashima Y, Mitsuhashi K, Tsubota Y, Miyata S, et al. Expression of trypsin by epithelial cells of various tissues, leukocytes, and neurons in human and mouse. Am J Pathol 1998;153:937-944.
18. Emi M, Nakamura Y, Ogawa M, Yamamoto T, Nishide T, Mori T, et al. Cloning, characterization and nucleotide sequences of two cDNAs encoding human pancreatic trypsinogens. Gene 1986;41:305-310.
19. Tani T, Kawashima I, Mita K, Takiguchi Y. Nucleotide sequence of the human pancreatic trypsinogen III cDNA. Nucleic Acids Res 1990;18:1631.
20. Wiegand U, Corbach S, Minn A, Kang J, Muller-Hill B. Cloning of the cDNA encoding human brain trypsinogen and characterization of its product. Gene 1993;136:167-175.
21. Imamura T, Kitamoto Y. Expression of enteropeptidase in differentiated enterocytes, goblet cells, and the tumor cells in human duodenum. Am J Physiol Gastrointest Liver Physiol 2003;285:G1235-G1241.
22. Miyata S, Koshikawa N, Higashi S, Miyagi Y, Nagashima Y, Yanoma S, et al. Expression of trypsin in human cancer cell lines and cancer tissues and its tight binding to soluble form of Alzheimer amyloid precursor protein in culture. J Biochem (Tokyo) 1999;125:1067-1076.
23. O'Keefe SJ, Lee RB, Li J, Stevens S, Abou-Assi S, Zhou W. Trypsin secretion and turnover in patients with acute pancreatitis. Am J Physiol Gastrointest Liver Physiol 2005;289:G181-G187.
24. Descamps FJ, Martens E, Ballaux F, Geboes K, Opdenakker G. In vivo activation of gelatinase B/MMP-9 by trypsin in acute pancreatitis is a permissive factor in streptozotocin-induced diabetes. J Pathol 2004;204:555-561.
25. Howes N, Greenhalf W, Stocken DD, Neoptolemos JP. Cationic trypsinogen mutations and pancreatitis. Gastroenterol Clin North Am 2004;33:767-787.
26. Stenman UH, Koivunen E, Itkonen O. Biology and function of tumor-associated trypsin inhibitor, TATI. Scand J Clin Lab Invest Suppl 1991;207:5-9.
27. Hirahara F, Miyagi E, Nagashima Y, Yasumitsu H, Koshikawa N, Nakatani Y, et al. Differential expression of trypsin in human ovarian carcinomas and low-malignant-potential tumours. Gynecol Oncol 1998;68:162-165.
28. Kawano N, Osawa H, Ito T, Nagashima Y, Hirahara F, Inayama Y, et al. Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study. Hum Pathol 1997;28:613-622.
29. Kato Y, Nagashima Y, Koshikawa N, Miyagi Y, Yasumitsu H, Miyazaki K. Production of trypsins by human gastric cancer cells correlates with their malignant phenotype. Eur J Cancer 1998;34:1117-1123.
30. Koivunen E, Saksela O, Itkonen O, Osman S, Huhtala ML, Stenman UH. Human colon carcinoma, fibrosarcoma and leukemia cell lines produce tumor-associated trypsinogen. Int J Cancer 1991;47:592-596.
31. Koivunen E, Ristimaki A, Itkonen O, Osman S, Vuento M, Stenman UH. Tumor-associated trypsin participates in cancer cell-mediated degradation of extracellular matrix. Cancer Res 1991;51:2107-2112.
32. Sorsa T, Salo T, Koivunen E, Tyynela J, Konttinen YT, Bergmann U, et al. Activation of type IV procollagenases by human tumor-associated trypsin-2. J Biol Chem 1997;272:21067-21074.
33. Alm AK, Gagnemo-Persson R, Sorsa T, Sundelin J. Extrapan-creatic trypsin-2 cleaves proteinase-activated receptor-2. Biochem Biophys Res Commun 2000;275:77-83.
34. Lukkonen A, Sorsa T, Salo T, Tervahartiala T, Koivunen E, Golub L, et al. Down-regulation of trypsinogen-2 expression by chemically modified tetracyclines: association with reduced cancer cell migration. Int J Cancer 2000;86:577-581.
35. Moilanen M, Sorsa T, Stenman M, Nyberg P, Lindy O, Vesterinen J, et al. Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-3) and degrades type I collagen. Biochemistry 2003;42:5414-5420.
36. Verspaget HW. Proteases as prognostic markers in cancer. BMJ 1998;316:790-791.
37. Heslin MJ, Yan J, Johnson MR, Weiss H, Diasio RB, Urist MM. Role of matrix metalloproteinases in colorectal carcinogenesis. Ann Surg 2001;233:786-792.
38. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4:839-849.
39. Leeman MF, Curran S, Murray GI. New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol 2003;201:528-534.
40. Moran A, Iniesta. P, Garcia-Aranda C, De Juan C, Diaz-Lopez A, Sanchez-Pernaute A, et al. Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer. Oncol Rep 2005;13:115-120.
41. Kioi M, Yamamoto K, Higashi S, Koshikawa N, Fujita K, Miyazaki K. Matrilysin (MMP-7) induces homotypic adhesion of human colon cancer cells and enhances their metastatic potential in nude mouse model. Oncogene 2003;22:8662-8670.
42. Turpeinen U, Koivunen E, Stenman UH. Reaction of a tumour-associated trypsin inhibitor with serine proteinases associated with coagulation and tumour invasion. Biochem J 1988;254:911-914.
43. Nishibori M, Mori S, Takahashi HK. Physiology and pathophysiology of proteinase-activated receptors (PARs): PAR-2-mediated proliferation of colon cancer cell. J Pharmacol Sci 2005;97:25-30.
44. Yada K, Shibata K, Matsumoto T, Ohta M, Yokoyama S, Kitano S. Protease-activated receptor-2 regulates cell proliferation and enhances cyclooxygenase-2 mRNA expression in human pancreatic cancer cells. J Surg Oncol 2005;89:79-85.
45. Darmoul D, Gratio V, Devaud H, Laburthe M. Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J Biol Chem 2004;279:20 927-20934.
46. Yamashita K, Mimori K, Inoue H, Mori M, Sidransky D. A tumor-suppressive role for trypsin in human cancer progression. Cancer Res 2003;63:6575-6578.
47. Uchima Y, Sawada T, Nishihara T, Umekawa T, Ohira M, Ishikawa T, et al. Identification of a trypsinogen activity stimulating factor produced by pancreatic cancer cells: its role in tumor invasion and metastasis. Int J Mol Med 2003;12:871-878.
48. Ducroc R, Bontemps C, Marazova K, Devaud H, Darmoul D, Laburthe M. Trypsin is produced by and activates protease-activated receptor-2 in human cancer colon cells: evidence for new autocrine loop. Life Sci 2002;70:1359-1367.
49. Bohe H, Bohe M, Lindstrom C, Ohlsson K. Immunohistochemical demonstration of pancreatic secretory trypsin inhibitor in normal and neoplastic colonic mucosa. J Clin Pathol 1990;43:901-904.
50. Bohe M, Borgstrom A, Lindstrom C, Ohlsson K. Pancreatic endoproteases and pancreatic secretory trypsin inhibitor immunoreactivity in human Paneth cells. J Clin Pathol 1986;39:786-793.
51. Tomita N, Doi S, Higashiyama M, Morimoto H, Murotani M, Kawasaki Y, et al. Expression of pancreatic secretory trypsin inhibitor gene in human colorectal tumor. Cancer 1990;66:2144-2149.
52. Higashiyama M, Monden T, Tomita N, Murotani M, Kawasaki Y, Morimoto H, et al. Expression of pancreatic secretory trypsin inhibitor (PSTI) in colorectal cancer. Br J Cancer 1990;62:954-958.
53. Solakidi S, Dessypris A, Stathopoulos GP, Androulakis G, Sekeris CE. Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alphal-antitrypsin in patients with gastrointestinal malignancies. Clin Biochem 2004;37:56-60.
54. Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 2004;23:101-117.
55. Wagenaar-Miller RA, Gordon L, Matrisian LM. Matrix metalloproteinases in colorectal cancer: is it worth talking about? Cancer Metastasis Rev 2004;23:119-135.
56. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-2392.
57. Zinzindohoue F, Lecomte T, Ferraz JM, Houllier AM, Cugnenc, PH, Berger A, et al. Prognostic significance of MMP-1 and MMP-3 functional promoter polymorphisms in colorectal cancer. Clin Cancer Res 2005;11:594-599.
58. Zeng ZS, Shu WP, Cohen AM, Guillem JG. Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: evidence for involvement of MMP-7 activation in human cancer metastases. Clin Cancer Res 2002;8:144-148.
59. Zeng ZS, Huang Y, Cohen AM, Guillem JG. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 1996;14:3133-3140.
60. Witty JP, McDonnell S, Newell KJ, Cannon P, Navre M, Tressler RJ, et al. Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res 1994;54:4805-4812.
61. Tien YW, Lee PH, Hu RH, Hsu SM, Chang KJ. The role of gelatinase in hepatic metastasis of colorectal cancer. Clin Cancer Res 2003;9:4891-4896.
62. Matsuyama Y, Takao S, Aikou T. Comparison of matrix metalloproteinase expression between primary tumours with or without liver metastasis in pancreatic and colorectal carcinomas. J Surg Oncol 2002;80:105-110.
63. Masaki T, Sugiyama M, Matsuoka H, Abe N, Izumisato Y, Sakamoto A, et al. Coexpression of matrilysin and laminin-5 gamma2 chain may contribute to tumor cell migration in colorectal carcinomas. Dig Dis Sci 2003;48:1262-1267.
64. Masaki T, Sugiyama M, Matsuoka H, Abe N, Izumisato Y, Sakamoto A, et al. Matrix metalloproteinases, may contribute compensationally to tumor invasion in T1 colorectal carcinomas. Anticancer Res 2003;23:4169-4173.
65. Masaki T, Matsuoka H, Sugiyama M, Abe N, Izumisato Y, Goto A, et al. Laminin-5 gamma 2 chain and matrix metalloproteinase-2 may trigger colorectal carcinoma invasiveness through formation of budding tumor cells. Anticancer Res 2003;23:4113-4119.
66. Masaki T, Matsuoka H, Sugiyama M, Abe N, Goto A, Sakamoto A, et al. Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas. Br J Cancer 2001;84:1317-1321.
67. Leeman MF, McKay JA, Murray GI. Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J Clin Pathol 2002;55:758-762.
68. Itoh F, Yamamoto H, Hinoda Y, Imai K. Enhanced secretion and activation of matrilysin during malignant conversion of human colorectal epithelium and its relationship with invasive potential of colon cancer cells. Cancer 1996;77:1717-1721.
69. Imai K, Yokohama Y, Nakanishi I, Ohuchi E, Fujii Y, Nakai N, et al. Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties. J Biol Chem 1995;270:6691-6697.
70. Saitoh Y, Yanai H, Higaki S, Nohara H, Yoshida T, Okita K. Relationship between matrix metalloproteinase-7 and pit pattern in early stage colorectal cancer. Gastrointest Endosc 2004;59:385-392.
71. Zeng ZS, Guillem JG. Colocalisation of matrix metalloproteinase9-mRNA and protein in human colorectal cancer stromal cells. Br J Cancer 1996;74:1161-1167.
72. Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R, Murray GI. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res 2004;10:8229-8234.
73. Roeb E, Arndt M, Jansen B, Schumpelick V, Matern S. Simultaneous determination of matrix metalloproteinase (MMP)-7, MMP-l, -3, and -13 gene expression by multiplex PCR in colorectal carcinomas. Int J Colorectal Dis 2004;19:518-524.
74. Gustavson MD, Crawford HC, Fingleton B, Matrisian LM. Tcf binding sequence and position determines beta-catenin and Lef-1 responsiveness of MMP-7 promoters. Mol Carcinog 2004;41:125-139.
75. Ougolkov AV, Yamashita K, Mai M, Minamoto T. Oncogenic beta-catenin and MMP-7 (matrilysin) cosegregate in late-stage clinical colon cancer. Gastroenterology 2002;122:60-71.
76. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase-activated receptors. Pharmacol Rev 2001;53:245-282.
77. Bohm SK, McConalogue K, Kong W, Bunnett NW. Proteinase-activated receptors: new functions for old enzymes. News Physiol Sci 1998;13:231-240.
78. Kanke T, Takizawa T, Kabeya M, Kawabata A. Physiology and pathophysiology of proteinase-activated receptors (PARs): PAR-2 as a potential therapeutic target. J Pharmacol Sci 2005;97:38-42.
79. Hollenberg MD. Physiology and pathophysiology of proteinase-activated receptors (PARs): proteinases as hormone-like signal messengers: PARs and more. J Pharmacol Sci 2005;97:8-13.
80. D'Andrea MR, Derian CK, Leturcq D, Baker SM, Brunmark A, Ling P, et al. Characterization of protease-activated receptor-2 immunoreactivity in normal human tissues. J Histochem Cytochem 1998;46:157-164.
81. Kunzelmann K, Schreiber R, Konig J, Mall M. Ion transport induced by proteinase-activated receptors (PAR2) in colon and airways. Cell Biochem Biophys 2002;36:209-214.
82. Mall M, Gonska T, Thomas J, Hirtz S, Schreiber R, Kunzelmann K. Activation of ion secretion via proteinase-activated receptor-2 in human colon. Am J Physiol Gastrointest Liver Physiol 2002;282:G200-G210.
83. Ohta T, Shimizu K, Yi S, Takamura H, Amaya K, Kitagawa H, et al. Protease-activated receptor-2 expression and the role of trypsin in cell proliferation in human pancreatic cancers. Int J Oncol 2003;23:61-66.
84. Cottrell GS, Amadesi S, Grady EF, Bunnett NW. Trypsin IV, a novel agonist of protease-activated receptors 2 and 4. J Biol Chem 2004;279:13 532-13 539.
85. Darmoul D, Marie JC, Devaud H, Gratio V, Laburthe M. Initiation of human colon cancer cell proliferation by trypsin acting at protease-activated receptor-2. Br J Cancer 2001;85:772-779.
86. Shi X, Gangadharan B, Brass LF, Ruf W, Mueller BM. Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res 2004;2:395-402.
87. Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL, Mandal SK, et al. Tissue factor-factor VIIa-specific upregulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 2004;103:3029-3037.
88. Lynch CC, Crawford HC, Matrisian LM, McDonnell S. Epidermal growth factor upregulates matrix metalloproteinase-7 expression through activation of PEA3 transcription factors. Int J Oncol 2004;24:1565-1572.
89. Mimori K, Yamashita K, Ohta M, Yoshinaga K, Ishikawa K, Ishii H, et al. Coexpression of matrix metalloproteinase-7 (MMP-7) and epidermal growth factor (EGF) receptor in colorectal cancer: an EGF receptor tyrosine kinase inhibitor is effective against MMP-7-expressing cancer cells. Clin Cancer Res 2004;10:8243-8249.
90. Shimamoto R, Sawada T, Uchima Y, Inoue M, Kimura K, Yamashita Y, et al. A role for protease-activated receptor-2 in pancreatic cancer cell proliferation. Int J Oncol 2004;24:1401-1406.
91. D'Andrea MR, Derian CK, Santulli RJ, Andrade-Gordon P. Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues. Am J Pathol 2001;158:2031-2041.
92. Gruber BL, Marchese MJ, Santiago-Schwarz F, Martin CA, Zhang J, Kew RR. Protease-activated receptor-2 (PAR-2) expression in human fibroblasts is regulated by growth factors and extracellular matrix. J Invest Dermatol 2004;123:832-839.
93. Kong W, McConalogue K, Khitin LM, Hollenberg MD, Payan DG, Bohm SK, et al. Luminal trypsin may regulate enterocytes through proteinase-activated receptor-2. Proc Natl Acad Sci USA 1997;94:8884-8889.
94. Cianchi F, Cortesini C, Fantappie O, Messerini L, Sardi I, Lasagna N, et al. Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer. Clin Cancer Res 2004;10:2694-2704.
95. Sun Y, Tang XM, Half E, Kuo MT, Sinicrope FA. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res 2002;62:6323-6328.
96. Wagenaar-Miller RA, Hanley G, Shattuck-Brandt R, DuBois RN, Bell RL, Matrisian LM, et al. Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction. Br J Cancer 2003;88:1445-1452.
97. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002;8:289-293.
98. Pai R, Nakamura T, Moon WS, Tarnawski AS. Prostaglandins promote colon cancer cell invasionsignaling by cross-talk between two distinct growth factor receptors. FASEB J 2003;17:1640-1647.
99. Bassi DE, Fu J, Lopez de Cicco R, Klein-Szanto AJ. Proprotein convertases: "master switches" in the regulation of tumor growth and progression. Mol Carcinog 2005;44:151-161.
100. Mbikay M, Sirois F, Yao J, Seidah NG, Chretien M. Comparative analysis of expression of the proprotein convertases furin, PACE4, PC1 and PC2 in human lung tumours. Br J Cancer 1997;75:1509-1514.
101. Khatib AM, Siegfried G, Prat A, Luis J, Chretien M, Metrakos P, et al. Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions. J Biol Chem 2001;276:30686-30693.
102. Lin SW, Cook M, Finnberg N, Bernhard E, Baldwin D, ElDeiry WS. p53-dependent induction of serine proteases in irradiated mouse colon. Cancer Biol Ther 2004;3:1290-1297.
103. Bettstetter M, Woenckhaus M, Wild PJ, Rummele P, Blaszyk H, Hartmann A, et al. Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer. J Pathol 2005;205:606-614.
104. Soreide K, Janssen EA, Soiland H, Korner H, Baak JP. Microsatellite instability in colorectal cancer. Br J Surg 2006;93:395-406.
105. Baak JP, Janssen EA, Soreide K, Heikillae R. Genomics and proteomics - the way forward. Ann Oncol 2005;16(Suppl2): ii33-ii44.